The

LAST CALL
PROGRAM

3-Step Do-It-Yourself Alcohol Program

Scientific Conclusions

84

PROVEN
SUCCESS RATE
2011 by Avantcare, Inc. Last Call Program (TM), Sobrexa (TM), Kalmaro (TM), and the contents of this site are the property of Avantcare, Inc.
Any sale, use, or reproduction of these materials without the express written consent of Avantcare, Inc. is strictly prohibited. All rights reserved.

The LAST CALL Program

Table of Contents

Foreword
Message from the Managing Director of Access Health Partners

Section A

Pages 4, 5

Alcohol Use Disorders and Addiction: Definition and Causes

Section B

Pages 6, 7

Sobrexa and the Last Call Program: What is it? How it works

Section C

Page 8

Neuroadaption: How the Brain Becomes Addicted to Alcohol

Section D

Page 9

Behavioral Neurobiology: How Alcohol Addiction Affects Behavior

Section E

Pages 10, 11

Representative Studies of Sobrexa: A Daidzin-based Compound

Section F

Pages 12, 13, 14, 15

The Case Study: 84% Proven and Verified Success Rate and Conclusions

The LAST CALL Program

or many years, our Access Health Partners leadership has set a high standard of excellence, serving people throughout
the U.S. in the health care industry. Specializing in offering affordable health insurance from top rated carriers has
earned us a strong reputation amongst peers in the field of medical technologies. In addition, our customer service
and client satisfaction has earned us an A score with the Better Business Bureau, which is a result of zero
complaints for the last 3 consecutive years.

As our influence continues to grow we are introduced to opportunities that can have a positive impact on our communities, our
families and our nation as it pertains to better health practices. As a result of this exposure, we would like to present an overview
of Avantcare, Inc.s Last Call Program in an effort to educate and inform the person or group whom sincerely desires to
understand the recent breakthroughs in the science of neuro-addiction and how the Last Call Program has changed the way
Alcohol Use Disorders (AUD) are approached.

Our founders first discovered the work of Dr. Frank Gibson and Avantcare, Inc. several years ago. His integrative medicinal
clinics at that time conducted over 10,000 patient visits per year and he had already appeared on over 52 radio and TV programs
including CNN and NBC. What was truly captivating however was his groundbreaking work in scientifically proven treatments for
alcohol use disorders. Having treated thousands of people suffering from the chemical imbalance brought on by alcohol use, the real life
results and simple application of his 8-week program was unprecedented.

The most compelling evidence presented, however, was the completion of an exhaustive 12-month private clinical study on 1100
participants in the Last Call Program. Conventional treatment programs demonstrate a 12 month average success rate of 16%, the Last
Call Program has proven an 84% success rate amongst participants who follow the program as directed.
Since rapid advances have occurred in such a wide range of areas, including neuroscience, genetics, epidemiology, health risks, prevention, and
treatment, the amount of information, while plentiful, can seem daunting to the average person. Addiction science can be researched and found but
is typically spread through thousands of studies, textbooks, and reports. Even medical practitioners can be overwhelmed as they now seek a more
contemporary understanding of the components of AUD and how the current knowledge contributes to development of the necessary treatment
strategies.
Access Healths legal team conducted an extensive due diligence, investigation and background check on all product development, manufacturing
standards, success claims and research studies available due to the obvious breakthrough implications. The result has led to a distribution agreement
with Avantcare, Inc. for the Last Call Program. The Last Call Program is currently being released in the U.S. and will continue to affect positively
the millions of people who suffer daily from excessive alcohol use.
The following Avantcare, Inc. booklet, The Last Call Program - Neurobiology And Addiction, written by Dr. Frank W. Gibson, provides an
opportunity to view the scientific conclusions in a concise form along with documentation that resulted from the Avantcare, Inc. independent case
studies.

Jamie Minton

Jamie Minton, Managing Director

Access Health Partners

Access Health Partners

7450 Dr. Phillips Blvd Suite 205
Orlando, FL 32819

Avantcare, Inc.
3937 Chimney Rock Rd #10
Edneyville, NC 28727

The LAST CALL Program

Alcohol Use Disorders (AUD) and Addiction:

Definition and Causes
According to available figures, 10 15% of people who drink alcohol will have an alcohol-related problem. This is due to a chemical imbalance that
occurs from years of drinking. That means that the vast majority (85-90%) of social drinkers never have a problem, simply enjoying alcohol as a normal
part of a healthy lifestyle. Last Calls goal is to help the 10-15% of the people assist their body in such a way that it can regain that chemical balance.
When this happens, their body is no longer reacting differently and instead it will respond to alcohol like a normal healthy adult. In order to demonstrate
how this can happen, we first need to define the issue and have a basic understanding of what is meant scientifically by chemical imbalance.

AUD Defined

Behavior associated with Alcohol Use Disorders is characterized by:

Loss of control over consumption
Development of tolerance and dependence
An unending vulnerability to relapse after attempting to abstain from drinking
Uncontrollable cravings to obtain alcohol
To understand the factors that compel some individuals to drink excessively, research has been focused on identifying chemical imbalances in the
brain that reinforce the actions of alcohol and show changes in neural (brain) function brought about by continual alcohol consumption. This
means that when a person suffers from AUD, they are dealing with a chemical issue that often goes well beyond their ability to use will power to
stop.
The conditions that lead to excessive alcohol use in some people and not others are complex because they involve genetics, environmental, and
neurobiological factors. Alcohol Use Disorder is clearly a multigenic disorder, which means one must take into consideration a persons genes at the
chromosome level if they are to fully understand how AUD could have occurred. This also points to evidence that AUD can be traced throughout a
persons family medical history. Recent discoveries as featured in the October 2010 issue of USA today point directly to a specific gene identified
by scientist that has a profound effect on how people respond to alcohol:
As quoted from USA Today October 2010:
Krik Wilhelmsen, a genetics professor at the University of North Carolina-Chapel Hill School of Medicine, says, This finding potentially
changes the paradigm about how we think about how alcohol affects the brain. About 10% to 20% of the population carries a version of the gene that
makes their brains especially sensitive to alcohol.
The gene carries the blueprint for an enzyme called CYP2E1, known to be involved in metabolizing ethanol alcohol as well as other molecules,
such as the pain-reliever acetaminophen, or Tylenol, and nicotine. People who carry the version of the CYP2E1 gene linked to increased
sensitivity to alcohol produce more of the enzyme. CYP2E1 affects how sensitive the brain is to alcohol.
CNN also produced a very compelling interview with Dr. Sanjay Gupta who was offered the position of Surgeon General of the United States in
the Obama administration in January of 2009. It was during this interview that he spent time with Dr. Bankole Johnson who runs the psychiatry
department at the University of Virginia. According to Dr. Johnson, 60% of addiction is biologically genetic, which means dependency on alcohol
can be inherited or passed along from generation to generation. You could have an addict in your family who hasnt even taken their first sip of
alcohol yet.

The LAST CALL Program

Conclusion
The Future

Alcohol Use Disorders (AUD) and Addiction: Definition and Causes

Science now understands Alcohol Use Disorders as a neurological chemical imbalance. The person suffering with AUD exhibits uncontrollable,
neurological compulsion. This explains why they cannot stop with one drink and in many cases end up drinking in excess, overpowered by their
brain chemical imbalance.

In the future, the most effective

treatment protocols for alcohol use
disorders must offer components
that address the actions of alcohol
(ethanol) on brain chemistry and
neuro-circuits.
They must offer a way to help the
body realign and get back into
balance chemically, which will
influence motivation and
reward, along with the ones
responsible for the shift to
dependence and relapse.

The LAST CALL Program

Sobrexa and the Last Call Program: What is it?

How it works.
Over 15 million Americans need alcohol treatment but less than 11% seek help. Of those 11%, 67% have been court-ordered or had a serious
intervention. We believe that is largely due to the fact that these individuals are given only two extremes for treatmenteither check themselves in or hide
it. There has not been a middle ground for effective treatment. Making the choice to go away for a 30-60 day program at great expense is difficult. It
also requires a commitment to surrendering your will, having others find out about the sensitive issue, and often times, can risk employment or higher
insurance rates. Last Call provides a safe anonymous opportunity to avoid the troubles associated with AUD, with no negative aspects to the treatment
and at a much lower cost.

What is it?

The Last Call Program is an 8-week treatment for people suffering from Alcohol Use Disorders (AUD). The program is designed to help restore
balance in the body at a chemical level, and has been scientifically proven (see Study provided) to reduce the desire to consume excess alcohol. It
has been shown to curb the cravings and normalize alcohol consumption.
As studies and private trials were conducted, however, it was determined that an individual suffering from AUD could take the recommended
dosage of Sobrexa and follow the elements of the program in their own home with the same level of success as the original 2-month clinic
treatment program. This eliminated the need for the high expense and required time-off to participate in a 2-month outpatient program, making it
much more affordable and accessible to the average person. Further verified by the independent study and client reviews, the program was then
redesigned in the form of a program that is mailed directly to the clients home. The program contains a user guide, dietary guide, instructional
exercise DVD and two Avantcare products called Sobrexa and Kalmaro. The program is sold through private clinics, online, and through the
corporate call center typically costing around $1,000 per person.

Whats in it?

All ingredients found in the products are all-natural herbal compounds and meet FDA requirements for structure/function claims. Each of the
phyto ingredients are certified free of contaminants and verified for authenticity and purity through independent laboratory testing. The lab meets
all cGMP and ISPE requirements and is in the final stage to obtain the coveted USP manufacturing standards, which is currently held by a very
small percentage of laboratory and production facilities in the world.
Sobrexa is the key compound found in the Last Call Program. Sobrexa is a Daidzin-based compound, which can be described as a bridge
between plant materials and drug chemistry. The primary isoflavone in Sobrexa, daidzin, has had tremendous press, in recent years, and
through 212 abstracts and studies ranging from Harvards McClean Hospital to Boston University, the evidence is clear that Daidzin based
compounds can bring about dramatic results. Many of these findings can be found online if you do a general search. 18 abstracts connected
with studies in this document under Daidzin-based studies representative of Sobrexa have been included for your reference.
Sobrexa has been scientifically proven, when consumed as directed, to completely reduce if not eliminate the cravings for excess alcohol. It is a
botanically-based compound using a unique method to obtain the highest degree of bio-availability from multiple plant materials. The structure of
the formulation creates actions and mechanisms far more complex and effective than any form of plant-based, natural product. The client receives 9
bottles in their program kit that are in the form of a liquid dropper and consumes the entire contents over the 8-week duration. Sobrexa can be
diluted in water for ease of consumption. It does not make alcohol taste bad nor have there been any known or reported side effects in over a
decade of use.
Kalmaro can be consumed as needed but is not required daily. The program includes 3 bottles of Kalmaro. Clients report that Kalmaro brings
about an enhanced sense of well-being, calmness and reduction in nervousness. When used with Sobrexa, these multiple treatment aspects
deliver superior results in a very short period of time. Like Sobrexa, Kalmaro, can also be diluted in water for ease of consumption and has had
no reported or known side effects.
When followed for the 8-week duration, the Last Call Program helps restore the balance in the brain allowing for an individual previously
suffering from AUD the ability to choose to either cut back the amount of alcohol they consume on a weekly basis or eliminate it entirely from
their life.

The LAST CALL Program

How it works:

Sobrexa and the Last Call Program: What is it? How it works.
When the client receives their shipment, they should begin taking Sobrexa as soon as possible.

Week 1
It is recommended that the individual begin the first week by taking the highest dosage in the 8-week program: 4 droppers (not drops) six
times per day for the first 7 days.
Allow the alcohol reduction to come naturally. To discontinue excessive alcohol use abruptly could bring alcohol withdrawal syndrome. Certainly, it
is prudent to be mindful of alcohol use but a natural reduction will occur. This not only may be a more safe method, but it helps to reinforce the
natural, correct functioning of the body. It increases the confidence and encourages more positive discipline and adherence to the Last Call
Program. Do not be overly-concerned with the amount of alcohol consumption in the first week, especially if you have been consuming alcohol
daily.

Weeks 28
For the 2nd-8th week the client should consume the normal amount of Sobrexa: 4 droppers (not drops) three times per day.
90% of clients who reach the 3rd 4th week typically begin to report profound changes in their drinking habits. Experience shows clients who use
Sobrexa for 6 weeks consistently reduce consumption by 70%. Each person is suggested to complete the program by consuming all of the available
Sobrexa that comes in the kit and over the duration of the 8-week program they will begin to naturally reverse and restore balance in their body.

Visualization
Alcohol
Daily
consumed
amount

100% equals
6-8 glasses
of wine or
beer

Sobrexa
100% equals
4 full droppers,
6x per day

100%

80%
60%

50%

Sobrexa

50%

40%

Alcohol

30%

Alcohol
20%

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Week 8

The LAST CALL Program

Neuroadaption: How the Brain becomes

addicted to Alcohol
Alcohol use disorder is defined by neural reorganization, or neuroplasticity. Neuroplasticity is when the brain and nervous system are subject to change,
both structurally and functionally, based on contributing factors in the environment. Alcohol has the ability to change the way the brain functions, causing
a dependency on alcohol. In addition to the extensive literature on the importance of brain reward circuits in the development of AUD, research has
focused on a contingent of neural systems that play central roles.

Fact One
Chronic exposure to alcohol
induces changes in neural
circuits that control
motivational processes,
including arousal, reward, and
stress.

Fact Two
These changes affect systems
utilizing the signaling molecules
dopamine, opioid peptides,
Gamma-amino-butyric acid,
glutamate, and serotonin, as
well as systems modulating the
brains stress response.

Fact Three
These neuroadaptations produce
changes in sensitivity to
alcohols effects following
repeated exposure and a
withdrawal state following
discontinuation of alcohol use.

Fact Four
Chronic alcohol exposure
results in persistent neural
deficits, some of which may
fully recover following extended
periods of abstinence. However,
the organism remains
susceptible to relapse, even after
years of abstinence.

Fact Five
Research focusing on
neurobiology has brought about
the development of more
effective treatment strategies.

Changes in the reinforcing value of alcohol during the transition from alcohol use and abuse to dependence reflect adaptive neural changes.
Multiple processes contribute to the increased motivation to seek alcohol.

Sensitization
Incentive sensitization research posits that alcohol activates a common neural system responsible for attributing incentive salience to events
and stimuli associated with activation of that system. In other words the liking of alcohols effects becomes closely associated with wanting
the alcohol-associated incentive stimuli. Following repeated alcohol exposure, this wanting transforms into pathological cravings.

Tolerance
Once tolerance to the pleasurable effects of alcohol develops, the individual requires gradually higher doses of alcohol to produce the same
effect previously experienced at lower doses. In a cyclical manner, these gradually increasing doses produce even more tolerance to the hedonic
effects of alcohol. An organism that is chronically exposed to alcohol develops tolerance to its functional effects, metabolic effects, and
reinforcing properties.

Withdrawal
Following chronic alcohol exposure, the removal of alcohol produces withdrawal symptoms, some of which increase the motivation to ingest
alcohol. Neurobiologically induced changes in regard to withdrawal symptoms simply implies dysregulation of the bodys internal equilibrium
in response to a sudden decrease in blood alcohol content.

The LAST CALL Program

Behavioral Neurobiology: How Alcohol Addiction

Affects Behavior
A neural circuit can be conceptualized as a series of nerve cells (neurons) that are interconnected and relay information related to a specific function.
Within the circuit, information is passed between neurons via electrochemical signaling. Activated neurons release chemical signaling molecules
(neurotransmitters) that bind to specific proteins (receptors) on other neurons. Depending on the neurotransmitter involved, this process leads to the
electrical excitation or inhibition of subsequent neurons in that circuit.

Because alcohol interacts with several neurotransmitter systems responsible for reward and stress feedback, these particular interactions produce
alcohols strong reinforcing effects. Research using pharmacological, molecular, imaging, genetic, and proteomic techniques has elucidated details of
these alcohol effects and have proven that these interactions result in changes in neuronal function that underlie the development of sensitization,
tolerance, withdrawal and dependence.
Specifically, alcohol has been shown to interact with at least five neurotransmitter systems in the brain:

1 Dopamine Systems
5 Serotonin Systems
Serotonin plays an important role in mediating alcohols
effects on the brain. Alcohol exposure alters several aspects of
serotonergic signal transmission in the brain. People with an
abnormal serotonin transporter function are likely to need
greater amounts of alcohol to attain the pleasurable feelings
associated with alcohol consumption. Interference with this
function extends or diminishes the cells exposure to
serotonin and can lead to psychological disorders including
depression, a prominent example. Antidepressant
medications act on the serotonin transporters to prolong the
neurotransmitters activity. Normally, serotonin is pumped
back into the nerve cell that released it after it was used once.
These drugs interrupt the process so that more serotonin is
available. Serotonin itself cannot pass from the bloodstream
to the brain.

Alcohol consumption, in fact even the anticipation that

alcohol will be available, produces dopamine release. (This
has been determined by the detection of increased dopamine
levels in the fluid outside neurons). Alcohol withdrawal
results in a decrease in dopamine function in dependent
individuals and contributes to withdrawal symptoms and
alcohol relapse.

4 Glutamate Systems
Glutamate is the major excitatory neurotransmitter in the
brain. It exerts its effects via several receptor subtypes
including the N-methyl-D-aspartate (NMDA) receptor.
Glutamate systems have long been implicated in the acute
reinforcing actions of alcohol. (It is interesting to note that
alcohol effects perceived by an organism can be mimicked
with NMDA antagonists). Alcohol disrupts glutamatergic
neurotransmission by inhibiting the response of the NMDA
receptor and by promoting neural toxicity through
upregulation of the NMDA receptor density. The
involvement of NMDA receptors also includes a process
characterized by neural reorganization (neuroplasticity) that
contributes to hyper-excitability and cravings during alcohol
withdrawal. Compounds targeting the glutamate systems are
being used in the treatment of alcohol dependence by
dampening excessive glutamate activity.

2 Opoid Systems
Neurotransmitter
Systems

Numerous studies demonstrate that positive alcohol

reinforcement is mediated at least in part by the release of
endogenous opioids in the brain. Endogenous opioids are
small molecules naturally produced in the body and have
long been implicated in the actions of alcohol. There are three
classes of endogenous opioids: endorphins, enkephalins, and
dynorphins. Complete inactivation of a subtype of opioid
receptors suppresses alcohol self-administration. The agent
naltrexone (currently approved as a treatment for alcoholism
in humans) is a subtype-nonspecific opioid receptor
antagonist.

3 Gamma Aminobutyric Acid

Systems (GABA)
Alcohol binds to GABA receptors and increases the quieting
effect GABA has on neurons. Because there are GABA
receptors in so many parts of the brain, this accounts for
alcohols sedating effects such as judgment, movement and
even breathing. While alcohols action of increasing the
quieting effect might seem like a good thing, prolonged
alcohol use causes neuroadaption. Unfortunately, the brain
comes to depend on the presence of alcohol to function
normally thus cessation brings about anxiety, tremors, and
even death.

10

The LAST CALL Program

Representative Studies of Sobrexa:

A Daidzin-based Compound
Led and encouraged by research over the past fifteen years by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the U.S. Food and Drug
Administration has placed some medications on a fast track for approval to meet the needs of the current knowledge of the neurobiology of addiction.
Most typically, these are drugs already approved by the FDA for other uses.

Advances in Addiction
Medications

The Director of the National Institute on Drug abuse, Dr. Nora Volkow has encouraged researchers to approach their studies by investigating the
underlying brain circuitry.
Continued use leads to changes in neuronal circuits that are evident well after a person stops taking an addictive substance.
A key in combating addiction is by working on a biological level as it changes brain circuitry and responses to cues, rather than temporarily
repressing or controlling the need to drink.
Medications currently approved for use are:

Medications in FDA Phase II or Phase III Trials or other studies:

ZOFRAN (ondansetron) class: 5HT3 receptor antagonist

SABRIL, currrently sold as Vigabtrin anticonvulsant

CAMPRAL (acamprosate) class: alcohol dependence

PRAZOSIN alcohol dependence

VIVITROL (naltrexone) class: alcohol dependence

NALMEFENE, Phase III alcohol dependence

ZOFRAN ODT (ondansetron) class: 5HT receptor antagonists

ALKS33, Phase II Opioid receptor modulator

REVIA (naltrexone) class: alcohol dependence

Quetiapine/Mirtazapine combination alcohol dependence

Chlorzoxazone, FDA approved muscle relaxant

The evidence and emphasis put forth by the FDA, NIDA, NIAA, NIH, pharmaceutical companies, and research centers, define the current needs
and the future of treatment.

Daidzin-based studies representative of SOBREXA

Including: Potentiation of Bioavailability, Antidipsotropic Agent, GABA Effect

SOBREXA is a Daidzin-based dietary supplement compound. Sobrexa was created for the marketplace in 1996 after nine years of research and
development. The product has also been presented under the names, Alco-eze and Fineta but is currently offered only through the Last Call
Program as an 8-week treatment.

Background
Known Effects

Daidzin is a natural organic compound in the class of phytochemicals known as isoflavones. Daidzin can be found in a variety of plants including
Pueraria Labato, Pueraria Condallei, Puraria Thomsonii,Pueraria thunbergiana, and others. Daidzin is the 7-0- glucoside of daidzein. ( Jin WS,
Tan YY, Chen YG, Wang Y January 2003) Determination of puerarin, daidzin and daidzein in root of Puerari Lobata of different origin by
HPLCJ).
Daidzin is proven to be an antidipsotropic agent. (Rezvani, A. 2003 Plant Derivatives in the Treatment of Alcohol Dependency Pharmacology
Biochemistry and Behavior) and (Keung WM, Vallee BL February 1998. Radix Puerariae: an ancient Chinese
source of modern antidipsotropic agents). Hundreds of studies have been performed on the isoflavone daidzin and isoflavonoid compounds
extracted from plants. These studies demonstrate that daidzin based compounds, such as Sobrexa, suppress alcohol preference, inhibit serotonin
and dopamine metabolism in isolated mitochondria, and suppresses voluntary alcohol intake and alcohol withdrawal.

11

The LAST CALL Program

Representative Studies of Sobrexa: A Daidzin-based Compound

Daidzin, an anti-drinking substance, inhibits human aldehyde dehydrogenase 2 (ALDH-2) which metabolizes alcohol into acetaldehyde.
Inhibiting ALDH-2 promotes the accumulation of acetaldehyde, which has aversive effects. Studies contained in this report show that daidzin
based compounds, such as Sobrexa, reduce drinking and prevents relapse by increasing acetaldehyde while drinking and later decreases dopamine in
the brain region that controls relapse during abstinence.

How it works

To ensure the completeness and consistency of the isoflavones from the plant materials, Sobrexa utilizes a simple, analytical method. This
quantification method of daidzin and genestein has been developed for routine quantification of a broad range of these isoflavones. The method
utilizes synthetic glucosides as internal standards.

Quantification

Additional Sobrexa Representative Studies are listed below characterizing hundreds more studies performed in the past decade on Daidzin based
compounds. A brief abstract for each study is offered. If further reading of the below abstracts is needed, you can find most if not all of them
through searching on the Internet.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Potentiation of the Bioavailability of Daidzin by an Extract of Radix Puerariae, Keung, Vallee. 1996. Harvard Medical School.
Determination of puerarin, daidzin and daidzein in root of Pueraria lobata of different origin by HPLCJ. Jin, Tan, Chen, Wang. 2003. Beijing Yuke Development
Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in parmocogenetic rat model of alcoholism. Lin, Guthrie, Mai, Lee. 1996. Indiana University
School of Medicine.
Daidzin, an antioxidant isoflavonoid decreases blood alcohol levels and shortens sleep time induced by ethanol intoxication. Xie, Lin, Lumeng, Wang, Zhao. 1994. Indiana
University School of Medicine.
Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. Keung, Vallee. 1998. Center for Biochemical Sciences and Medicine,
Harvard Medical School.
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin. Rooke, Li, Keung. 2000. Harvard Medical School.
Kudzu root extract suppresses voluntary alcohol intake and alcohol withdrawal symptoms in P rats receiving free access to water and alcohol. Benlhabib, Baker, Keyler Singh.
University of Minnesota
Daidzin decreases ethanol consumption in rats. Heyman, Keung, Vallee. 1996. Department of Psychology, Harvard University.
Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin. Keung. 2001, Center for Biochemical and Biophysical
Sciences and Medicine, Harvard Medical School.
Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-828 and its derivatives. Overstreet, Lee, Ravani, Pei 1996. University of North Carolina,
School of Medicine.
Suppression of heavy drinking and alcohol seeking by a selective ALDH -2 inhibitor. Arolto, Overstreet, Yao, Keung, Vallee, 2009. CV Therapeutics, Palo Alto, CA
Kudzu root: an ancient Chinese source of modern antidipsotropic agents. Keung, Vallee 1998. Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical
School
Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence. Keung, 2003. Department of Psychiatry, Massachusetts Mental Health Center and Harvard
Medical School.
Gamma-vinyl GABA decreases voluntary alcohol consumption in alcohol preferring AA rats. Wegelius, Halonen, Korpi. 1993 Biomedical Research Center, Helsinki, Finland.
Plant derivative in the treatment of alcohol dependency. Rezvani, Overstreet, Perfumi. 2003. Department of Psychiatry, Duke Medical Center
Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. McBride, Li. 1998 . Department of Psychiatry, Indiana University School of Medicine
Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcohol-related disorders in P rats receiving
free choice water and 15% ethanol in pure water. Singh, Jiang, Bdnihabib, Gupta. 2007. University of Minnesota.
An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting. Lukas SE, Penetar D, Berko J, Vicens L, Palmer C, Mallya G,
Macklin EA, Lee DY. 1995 Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, Massachusetts 02478, USA

12

The LAST CALL Program

The Case Study:

84% Proven and Verified Success Rate
The following is a comparative analysis of Conventional Treatment for Alcohol Use Disorder (AUD) and 1136 monitored participants who were utilizing
Sobrexa and Kalmaro in combination with the Last Call Program.

The data of the findings has been consistently verifed through statistical analysis.

Study of the Avantcare Neutraceuticals Sobrexa and Kalmaro

in combination with the Last Call Program.

Abstract

The Abstract states the problem and purpose of the study and quoted sources. The purpose for the study was due to the fact that AUD affects
millions of people, the majority of accepted treatments is behavioral only, and there is a high degree of relapse associated with Conventional
Treatments. Sources below:
Alcohol Use Disorder (AUD) affects nearly 10% of the US population and causes marked medical morbidity and mortality, marked psychiatric
morbidity, increased health care costs, and lost work hours. Saxon, Malte, Sloan, et al, 2006. Thaneenmit-Chen, et al, 2007
AUD is a biologically, genetically based disease, yet the majority of clinically accepted treatments are behaviorally or psychosocially based.
Anton, ONakketmCiraulo, et al, 2006. Todd, Armali, Tennan, et al 2006
Despite the initial success of these treatments, 40 70% relapse within the first 12 months after treatment. McClinnis, E. Faogo, 1999
The need for more biological treatments along with the understanding that AUD is clearly a multi-genetic disorder led to the development of a
complete program. The program was created to address interactions among genetic, psychosocial, environmental, and neurobiological factors.
Recent advances in understanding the neurobiology of substance dependence and relapse support the notion that adrenergic (chemical) systems
play a critical role in these processes and, when combined with an educational component, lead to greatly increased success rates.

Study Details

The study is a comparative analysis of Conventional Treatment and The Last Call Program.
To establish the standard for the definition of Conventional Treatment, we began with an analysis of 928 treatment centers in the U.S. Details of
the Conventional Treatment data obtained are as follows:
Success statistics are sourced from a multiple of independent research facilities and medical schools fully accredited either the Joint
Commission for the Accreditation of Healthcare Organizations, or the Commission for the Accreditation of Rehabilitation Facilities.
874 of these treatment centers included the Alcoholics Anonymous (AA) 12 step program either as the entire treatment principle or as some
part combined with psychotherapy. Only 54 out of the 928 included in the study did not use any principles from the 12 Step Program.
The Last Call Program participants were categorized according to dependence and goals using the Alcohol Dependence Scale (Skinner and Allen,
1982) and the Last Call Program Study Questionnaire. The documentation and data presented from this study were obtained as follows:
Study participant statistics must include 6-month and 12-month participant administrator and written appraisals.
The results were consistently verified through independent statistical analysis.
Success in the program was defined as not having unusual cravings for alcohol and following Last Call Program post-program guidelines.
Problem drinkers were preferred for the study because they:
Account for a larger share of alcohol-related harm to society (e.g. domestic violence, alcohol- related fatalities,
workplace injuries) than do alcohol dependent individuals. Sobell, Cunningham, & Sobell, 1996
Are the largest segment (NIAAA)
Are less likely to enter a 28+day treatment program since they do not consider their behavior a consistent problem

13

The LAST CALL Program

Inclusion Criteria
Exclusion Criteria

Last Call Program

Requirements

The Case Study: 84% Proven and Verified Success Rate

included current primary DSM-IV diagnosis for AUD, heavy drinking in the previous 30 days, at least 21 years of age, good general medical health
(see Exclusion Criteria below), the capacity to provide informed consent, English fluency, and home-partnership with family member, relative, or
friend.
included psychiatric disorders requiring any medication other than anti-depressants. To ensure that no other drugs could enhance or alter the
affects of Sobrexa, no participants currently taking disulfram, acamprosate or naltrexone were included in the case study. Also, no current
dependence on any other psychoactive substance other than nicotine or cannabis, a current diagnosis of apioid abuse, use of any apioid containing
medications or benzodiazepines during the previous 30 days, medical significant acute or chronic medical illness, or legal involvement that could
interfere with the study treatment (no court-orders for treatment).
Participants were required to enroll in an 8-week program which utilized multiple modalities. The Last Call Program included:
Sobrexa daidzin-based compound taken orally 3 times daily 59mg /week
Kalmaro taken orally daily as needed
Dietary Guidelines USDA nutritional guidelines with liver focus
Stress Release Techniques relief from anxiety and stress Sleep Exercises DVD and written exercise program 10-15 minutes as specifically prescribed
Participant Program Evaluation and Reporting weekly with administrator Home Partner Component incl. weekly outlined discussions with family

Demographic Profile

Gender

68%

32%

Age
21-34

11%

35-45

54%

Education

No college

14%

50-59

27%

College

59 %

60+

8%

Graduate degree

21%

Not defined

6%

Income
est.
$30k $60k

19%

$61k $100k

33%

$101k +

27%

Undefined

21%

14

The LAST CALL Program

The Case Study: 84% Proven and Verified Success Rate

Comparative Analysis of Conventional Treatments to The Last Call Program

Percent that
started and completed
the program

Six-week
good treatment response

91

89

The

LAST CALL
PROGRAM

20

The

19nt%
al
ion ts

ALL
ST C

LAOGRAM
PR

nts

atme
al tre
n
o
i
22nv%
t
en

19%
conventional treatments

20

6 month and 12 month

success rate
of the program

40

60

ve en
contreatm

94

co

80

60

40

Percent that
could successfully control
alcohol withdrawal and
cravings after completion

The

LAST CALL
PROGRAM

80

Referral for
inpatient detoxification
after the program

Percent that undertook

positive initiatives
after the program

88

80

PROGRAM

84

0%

40

46%
20

The

LAST CALL

89%

60

80

conventional
treatments

16%
after
6 months

after
12 months

76%
conventional treatments

The

LAST CALL
PROGRAM

The

LAST CALL
PROGRAM

60
40

20

48%

conventional
treatments

15

The LAST CALL Program

Conclusion

The Case Study: 84% Proven and Verified Success Rate

It has been independently verified that of 1136 participants who followed the suggested Last Call Program 8-week suggested format which
includes Sobrexa, 955 of the participants reported success defined as no longer having unusual excessive cravings for alcohol.
This 84% success rate was measured after 12 months of completing the program.
Additionally, none of the 1100 participants required inpatient detoxification, and 968 participants reported that they undertook positive initiatives
such as restoring relationships, salvaged their families, and began a health routine in their daily lifestyle.

84

PROVEN
SUCCESS RATE

The

LAST CALL
PROGRAM

Thank
you
for your interest in The Last Call Program!

Questions?
Contact:

Customer Care Support Team

available 24 hours/day

support@lastcallprogram.com
1-800 209-0816

The

LAST CALL
PROGRAM

3-Step Do-It-Yourself Alcohol Program